Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diet-driven Gut Microbiome and Outcome in Patients With Early-stage Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy and Immunotherapy.

NCT07551765 is registered in ClinicalTrials.gov with Barts & The London NHS Trust as lead sponsor.

NCT NCT07551765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07551765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Diet-driven Gut Microbiome and Outcome in Patients With Early-stage Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy and Immunotherapy.
Lead sponsor
Barts & The London NHS Trust
Phase
Observational
Overall status
Not yet recruiting
Start date
November 13, 2026
Completion date
November 1, 2032
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer (tnbc), early setting